Cellular Biomedicine Group Inc. (CBMG) 29.51 $CBMG
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cellular Biomedicine Group Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of June 22, 2015 -- CBMG
GlobeNewswire - Thu Apr 23, 1:01PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
CBMG: 29.51 (-1.85)
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Cellular Biomedicine Group, Inc. (CBMG)
GlobeNewswire - Wed Apr 22, 6:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities that purchased the securities of Cellular Biomedicine Group Inc. ("Cellular" or the "Company"
(Nasdaq:CBMG) between June 18, 2014 and April 7, 2015, inclusive (the "Class Period" , alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint" .
CBMG: 29.51 (-1.85)
EQUITY ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Cellular Biomedicine Group Inc. - CBMG
Business Wire - Wed Apr 22, 5:41PM CDT
The Rosen Law Firm, a global investor rights firm, announces that a class action lawsuit has been filed on behalf of purchasers of Cellular Biomedicine Group Inc. (NASDAQ:CBMG) securities from June 18, 2014 through April 7, 2015. The lawsuit seeks to recover damages for Cellular Biomedicine investors under the federal securities laws.
CBMG: 29.51 (-1.85)
Pomerantz Law Firm Announces the Filing of a Class Action Against Cellular Biomedicine Group Inc. and Certain Officers -- CBMG
GlobeNewswire - Wed Apr 22, 9:21AM CDT
Pomerantz LLP announces that a class action lawsuit has been filed against Cellular Biomedicine Group Inc. ("CBMG" or the "Company" (Nasdaq:CBMG) and certain of its officers. The class action, filed in United States District Court, Northern District of California, and docketed under 15-cv-01795, is on behalf of a class consisting of all persons or entities who purchased CBMG securities between June 18, 2014 and April 7, 2015 inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" and Section 17(b) of the Securities Act of 1933.
CBMG: 29.51 (-1.85)
Cellular Biomedicine Group Announces New Facility in Beijing
GlobeNewswire - Wed Apr 22, 8:39AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company" , a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that the Company, in anticipation of growth in the Beijing vicinity and further development of the CAR-T platform, has signed a new five-year lease for a 15,000 square feet site slated for the Company's third GMP facility which will also expanded staffing in the Life Science Park, Changping District, Beijing, China. Approximately half of the site will be a GMP equipped facility to support clinical batch production and commercial scale manufacturing. We expect to complete the state-of-the-art GMP facility in Q3 this year.
CBMG: 29.51 (-1.85)
Quarterly Report Card: Special Research on Cellular Biomedicine, CIFC Corp., Consumer Portfolio Services, Credit Acceptance, and Home Loan Servicing
PR Newswire - Tue Apr 21, 8:54AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CIFC: 7.45 (-0.29), CACC: 216.38 (+5.39), CPSS: 6.76 (+0.07), CBMG: 29.51 (-1.85), HLSS: 17.19 (unch)
Cellular Biomedicine Group Engages Huntsworth Health to Build Global KOL Advocacy for Knee Osteoarthritis Stem Cell ReJoin(TM) Clinical Trials
GlobeNewswire - Mon Apr 20, 8:20AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company" , a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that the Company has engaged Huntsworth Health, a global healthcare marketing and communications agency to build a global KOL advocacy campaign for CBMG's ReJoin human adipose-derived mesenchymal progenitor cell (haMPC) clinical trials for the treatment of Knee Osteoarthritis.
CBMG: 29.51 (-1.85)
Cellular Biomedicine Group to Present at 10th Annual World Stem Cells & Regenerative Medicine Congress in London, UK
GlobeNewswire - Fri Apr 17, 8:15AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company" , a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that management has been invited to present at the 10 Annual World Stem Cells & Regenerative Medicine Congress to be held at the Business Design Centre in London, UK on May 20-22, 2015.
CBMG: 29.51 (-1.85)
Cellular Biomedicine Group Announces Participation in Jefferies 2015 Global Healthcare Conference
GlobeNewswire - Thu Apr 16, 6:39AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company" , a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that the management is scheduled to participate in the Jefferies 2015 Global Healthcare Conference to be held in New York on June 1-4, 2015.
CBMG: 29.51 (-1.85)
Cellular Biomedicine Group Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into Allegations of Corporate Wrongdoing
PR Newswire - Wed Apr 15, 10:30AM CDT
Securities lawyers at Dunnam & Dunnam are investigating allegations for Cellular Biomedicine Group Inc. shareholders (NASDAQ: CBMG). Concerned CBMG investors who purchased shares are encouraged to contact securities attorney Hamilton Lindley by clicking here.
CBMG: 29.51 (-1.85)
Cerebral Palsy Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Mon Apr 13, 5:30AM CDT
The report "Cerebral Palsy - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic developments for Cerebral Palsy. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cerebral-pal...eport.html .
AGN: 240.22 (+2.88), CBMG: 29.51 (-1.85)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 401.71 (-28.57), SPHS: 0.80 (-0.03), ADMS: 17.70 (-0.03), TKMR: 18.75 (-0.25), CBYL: 7.45 (-0.11), HPTX: 45.97 (-0.11), QURE: 26.09 (-0.28), SHPG: 255.11 (-0.26), SRPT: 13.42 (-0.24), HZNP: 31.75 (+0.97), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), ABBV: 66.07 (+1.82), CBMG: 29.51 (-1.85), ARNA: 4.49 (+0.05), EXEL: 3.08 (-0.02), ADXS: 23.34 (-0.27), PTLA: 38.51 (-0.85), BMY: 65.80 (-0.20), OCUL: 25.36 (-1.12), NVO: 56.65 (+0.44), DVA: 83.91 (+0.50), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), ALXN: 180.08 (-4.50), NVS: 104.28 (-1.22)
Nasdaq stocks posting largest percentage increases
AP - Fri Apr 10, 12:25PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
VUZI: 6.23 (+0.02), SBSA: 5.78 (-0.03), EBIO: 11.19 (+0.69), STAA: 9.14 (+0.02), APOG: 53.48 (+0.55), MARA: 6.06 (+0.29), CBMG: 29.51 (-1.85), VLTC: 11.54 (+0.50), ORPN: 6.40 (-0.01), DGLY: 13.88 (+0.39), REPH: 11.88 (+1.04)
3 Stocks Breaking Out on Unusual Volume
at The Street - Fri Apr 10, 12:25PM CDT
These stocks rising on big volume are within range of triggering breakout trades.
RAI: 76.26 (-0.71), CMG: 637.50 (+1.90), CBMG: 29.51 (-1.85)
Cellular Biomedicine Group to Present at ChinaBio(R) Partnering Forum in Shanghai on April 16, 2015
GlobeNewswire - Fri Apr 10, 8:32AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company" , a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, announced that they have been selected to present at the seventh annual ChinaBio(R) Partnering Forum 2015 to be held in Shanghai (April 15-16, 2015) at the Kerry Hotel Pudong in Shanghai, China. This life science industry event is expected to attract over 800 attendees from around the world focused on developing cross-border relationships in China.
CBMG: 29.51 (-1.85)
Cellular Biomedicine Group Upgraded to NASDAQ Global Market
GlobeNewswire - Fri Apr 10, 6:30AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company" , a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that it received notice that the NASDAQ Listing Qualifications Department has approved an application to upgrade the listing of the Company's securities from the NASDAQ Capital Market to the NASDAQ Global Market, effective with the opening of business on April 10, 2015. The NASDAQ Global Market is the segment for public companies that meet the higher listing standards of NASDAQ with requirements that include market value, financial and liquidity measurements and corporate governance standards.
CBMG: 29.51 (-1.85)
Cellular Biomedicine Group Hosts Open House Titled "Advancing Solutions to Cancerous and Degenerative Straits" on April 17, 2015
GlobeNewswire - Wed Apr 08, 11:01AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company" , a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced the Company will host an open house titled "Advancing Solutions to Cancerous and Degenerative Straits" following the China BIO conference in Shanghai on April 17, 2015 beginning at 8:30 a.m. located at the Company's facility at 333 Guiping Road, Building 1, Caohejing High Technology Park, Shanghai, China.
CBMG: 29.51 (-1.85)
Cellular Biomedicine Group Responds to False Statements and Allegations Made by Short Seller
GlobeNewswire - Wed Apr 08, 8:52AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company" , a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today responded to false statements and allegations made by Pump Stopper on April 7, 2015. The Company fully respects the right of any third party to express its opinion but reminds investors that facts are facts.
CBMG: 29.51 (-1.85)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cellular Biomedicine Group Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of June 22, 2015 -- CBMG
GlobeNewswire - Thu Apr 23, 1:01PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
CBMG: 29.51 (-1.85)
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Cellular Biomedicine Group, Inc. (CBMG)
GlobeNewswire - Wed Apr 22, 6:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities that purchased the securities of Cellular Biomedicine Group Inc. ("Cellular" or the "Company"
(Nasdaq:CBMG) between June 18, 2014 and April 7, 2015, inclusive (the "Class Period" , alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint" . CBMG: 29.51 (-1.85)
EQUITY ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Cellular Biomedicine Group Inc. - CBMG
Business Wire - Wed Apr 22, 5:41PM CDT
The Rosen Law Firm, a global investor rights firm, announces that a class action lawsuit has been filed on behalf of purchasers of Cellular Biomedicine Group Inc. (NASDAQ:CBMG) securities from June 18, 2014 through April 7, 2015. The lawsuit seeks to recover damages for Cellular Biomedicine investors under the federal securities laws.
CBMG: 29.51 (-1.85)
Pomerantz Law Firm Announces the Filing of a Class Action Against Cellular Biomedicine Group Inc. and Certain Officers -- CBMG
GlobeNewswire - Wed Apr 22, 9:21AM CDT
Pomerantz LLP announces that a class action lawsuit has been filed against Cellular Biomedicine Group Inc. ("CBMG" or the "Company"
(Nasdaq:CBMG) and certain of its officers. The class action, filed in United States District Court, Northern District of California, and docketed under 15-cv-01795, is on behalf of a class consisting of all persons or entities who purchased CBMG securities between June 18, 2014 and April 7, 2015 inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" and Section 17(b) of the Securities Act of 1933. CBMG: 29.51 (-1.85)
Cellular Biomedicine Group Announces New Facility in Beijing
GlobeNewswire - Wed Apr 22, 8:39AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"
, a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that the Company, in anticipation of growth in the Beijing vicinity and further development of the CAR-T platform, has signed a new five-year lease for a 15,000 square feet site slated for the Company's third GMP facility which will also expanded staffing in the Life Science Park, Changping District, Beijing, China. Approximately half of the site will be a GMP equipped facility to support clinical batch production and commercial scale manufacturing. We expect to complete the state-of-the-art GMP facility in Q3 this year. CBMG: 29.51 (-1.85)
Quarterly Report Card: Special Research on Cellular Biomedicine, CIFC Corp., Consumer Portfolio Services, Credit Acceptance, and Home Loan Servicing
PR Newswire - Tue Apr 21, 8:54AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CIFC: 7.45 (-0.29), CACC: 216.38 (+5.39), CPSS: 6.76 (+0.07), CBMG: 29.51 (-1.85), HLSS: 17.19 (unch)
Cellular Biomedicine Group Engages Huntsworth Health to Build Global KOL Advocacy for Knee Osteoarthritis Stem Cell ReJoin(TM) Clinical Trials
GlobeNewswire - Mon Apr 20, 8:20AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"
, a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that the Company has engaged Huntsworth Health, a global healthcare marketing and communications agency to build a global KOL advocacy campaign for CBMG's ReJoin human adipose-derived mesenchymal progenitor cell (haMPC) clinical trials for the treatment of Knee Osteoarthritis. CBMG: 29.51 (-1.85)
Cellular Biomedicine Group to Present at 10th Annual World Stem Cells & Regenerative Medicine Congress in London, UK
GlobeNewswire - Fri Apr 17, 8:15AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"
, a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that management has been invited to present at the 10 Annual World Stem Cells & Regenerative Medicine Congress to be held at the Business Design Centre in London, UK on May 20-22, 2015. CBMG: 29.51 (-1.85)
Cellular Biomedicine Group Announces Participation in Jefferies 2015 Global Healthcare Conference
GlobeNewswire - Thu Apr 16, 6:39AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"
, a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that the management is scheduled to participate in the Jefferies 2015 Global Healthcare Conference to be held in New York on June 1-4, 2015. CBMG: 29.51 (-1.85)
Cellular Biomedicine Group Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into Allegations of Corporate Wrongdoing
PR Newswire - Wed Apr 15, 10:30AM CDT
Securities lawyers at Dunnam & Dunnam are investigating allegations for Cellular Biomedicine Group Inc. shareholders (NASDAQ: CBMG). Concerned CBMG investors who purchased shares are encouraged to contact securities attorney Hamilton Lindley by clicking here.
CBMG: 29.51 (-1.85)
Cerebral Palsy Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Mon Apr 13, 5:30AM CDT
The report "Cerebral Palsy - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic developments for Cerebral Palsy. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cerebral-pal...eport.html .
AGN: 240.22 (+2.88), CBMG: 29.51 (-1.85)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 401.71 (-28.57), SPHS: 0.80 (-0.03), ADMS: 17.70 (-0.03), TKMR: 18.75 (-0.25), CBYL: 7.45 (-0.11), HPTX: 45.97 (-0.11), QURE: 26.09 (-0.28), SHPG: 255.11 (-0.26), SRPT: 13.42 (-0.24), HZNP: 31.75 (+0.97), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), ABBV: 66.07 (+1.82), CBMG: 29.51 (-1.85), ARNA: 4.49 (+0.05), EXEL: 3.08 (-0.02), ADXS: 23.34 (-0.27), PTLA: 38.51 (-0.85), BMY: 65.80 (-0.20), OCUL: 25.36 (-1.12), NVO: 56.65 (+0.44), DVA: 83.91 (+0.50), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), ALXN: 180.08 (-4.50), NVS: 104.28 (-1.22)
Nasdaq stocks posting largest percentage increases
AP - Fri Apr 10, 12:25PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
VUZI: 6.23 (+0.02), SBSA: 5.78 (-0.03), EBIO: 11.19 (+0.69), STAA: 9.14 (+0.02), APOG: 53.48 (+0.55), MARA: 6.06 (+0.29), CBMG: 29.51 (-1.85), VLTC: 11.54 (+0.50), ORPN: 6.40 (-0.01), DGLY: 13.88 (+0.39), REPH: 11.88 (+1.04)
3 Stocks Breaking Out on Unusual Volume
at The Street - Fri Apr 10, 12:25PM CDT
These stocks rising on big volume are within range of triggering breakout trades.
RAI: 76.26 (-0.71), CMG: 637.50 (+1.90), CBMG: 29.51 (-1.85)
Cellular Biomedicine Group to Present at ChinaBio(R) Partnering Forum in Shanghai on April 16, 2015
GlobeNewswire - Fri Apr 10, 8:32AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"
, a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, announced that they have been selected to present at the seventh annual ChinaBio(R) Partnering Forum 2015 to be held in Shanghai (April 15-16, 2015) at the Kerry Hotel Pudong in Shanghai, China. This life science industry event is expected to attract over 800 attendees from around the world focused on developing cross-border relationships in China. CBMG: 29.51 (-1.85)
Cellular Biomedicine Group Upgraded to NASDAQ Global Market
GlobeNewswire - Fri Apr 10, 6:30AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"
, a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that it received notice that the NASDAQ Listing Qualifications Department has approved an application to upgrade the listing of the Company's securities from the NASDAQ Capital Market to the NASDAQ Global Market, effective with the opening of business on April 10, 2015. The NASDAQ Global Market is the segment for public companies that meet the higher listing standards of NASDAQ with requirements that include market value, financial and liquidity measurements and corporate governance standards. CBMG: 29.51 (-1.85)
Cellular Biomedicine Group Hosts Open House Titled "Advancing Solutions to Cancerous and Degenerative Straits" on April 17, 2015
GlobeNewswire - Wed Apr 08, 11:01AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"
, a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced the Company will host an open house titled "Advancing Solutions to Cancerous and Degenerative Straits" following the China BIO conference in Shanghai on April 17, 2015 beginning at 8:30 a.m. located at the Company's facility at 333 Guiping Road, Building 1, Caohejing High Technology Park, Shanghai, China. CBMG: 29.51 (-1.85)
Cellular Biomedicine Group Responds to False Statements and Allegations Made by Short Seller
GlobeNewswire - Wed Apr 08, 8:52AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"
, a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today responded to false statements and allegations made by Pump Stopper on April 7, 2015. The Company fully respects the right of any third party to express its opinion but reminds investors that facts are facts. CBMG: 29.51 (-1.85)
